Hologic, Inc.

HOLX

US4364401012

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-17 EDT			5-day change	1st Jan Change
75.02 ^USD	+0.09%		-0.96%	+5.00%

05-09	Argus Adjusts Price Target on Hologic to $95 From $89	MT
05-06	Lumos Diagnostics Concludes Initial Phase of Development Deal with Hologic for Fetal Fibronectin Test; Shares Jump 6%	MT

Hologic, Inc. Reports Impairment of Intangible Assets for the Second Quarter Ended March 30, 2024

May 02, 2024 at 04:01 pm

Hologic, Inc. reported impairment of intangible assets for the second quarter ended March 30, 2024. For the quarter, the company reported impairment of intangible assets of $26.8 million.

Latest news about Hologic, Inc.

Argus Adjusts Price Target on Hologic to $95 From $89	05-09	MT
Lumos Diagnostics Concludes Initial Phase of Development Deal with Hologic for Fetal Fibronectin Test; Shares Jump 6%	05-05	MT
JPMorgan Adjusts Price Target on Hologic to $91 From $85	05-03	MT
UBS Adjusts Price Target on Hologic to $81 From $79, Maintains Neutral Rating	05-03	MT
Hologic Fiscal Q2 Earnings, Revenue Decline; Q3 Outlook Issued, Fiscal 2024 Estimates Revised -- Shares Up After Hours	05-02	MT
Transcript : Hologic, Inc., Q2 2024 Earnings Call, May 02, 2024	05-02
Earnings Flash (HOLX) HOLOGIC Posts Q2 EPS $1.03, vs. Street Est of $0.98	05-02	MT
Earnings Flash (HOLX) HOLOGIC Reports Q2 Revenue $1.02B, vs. Street Est of $1B	05-02	MT
(HOLX) HOLOGIC Expects Fiscal Year 2024 EPS Range $4.02 - $4.12	05-02	MT
(HOLX) HOLOGIC Sees Q3 EPS Range $0.98 - $1.05	05-02	MT
Hologic, Inc. Reports Impairment of Intangible Assets for the Second Quarter Ended March 30, 2024	05-02	CI
Hologic, Inc. Revises Earnings Guidance for the Fiscal Year 2024	05-02	CI
Hologic, Inc. Provides Earnings Guidance for the Third Quarter of Fiscal 2024	05-02	CI
Hologic, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 30, 2024	05-02	CI
Molten Ventures portfolio firm gets bought by Hologic	04-30	AN
Molten Ventures portfolio firm to buy Endomagnetics for USD310 million	04-30	AN
Hologic to Acquire Breast Cancer Surgery Technology Firm Endomagnetics For $310 Million	04-29	MT
Hologic, Inc. signed a definitive agreement to acquire Endomagnetics Ltd. for approximately $310 million.	04-28	CI
Bayer and Hologic Collaborates to Deliver Contrast-Enhanced Mammography	04-11	CI
Transcript : Hologic, Inc. Presents at 23rd Annual Needham Virtual Healthcare Conference, Apr-09-2024 11:45 AM	04-09
RBC Raises Price Target on Hologic to $81 From $76, Keeps Sector Perform Rating	04-08	MT
North American Morning Briefing : Focus Turns to -2-	04-04	DJ
Citigroup Upgrades Hologic to Buy From Neutral, Raises Price Target to $95 From $80	04-03	MT
Watching for Indications of a Changed Fed Outlook; Plus, How One Company Avoided Mass Layoffs	03-20	DJ
Hologic Insider Sold Shares Worth $1,241,296, According to a Recent SEC Filing	03-15	MT

Hologic, Inc. is the world leader in the design, manufacturing and marketing of diagnostic products, medical imaging systems and surgical products dedicated to women's health. Net sales break down by area of application as follows: - molecular diagnostics (46.7%): rapid diagnostic tests for human diseases detection (sexually transmitted infections, respiratory diseases, viral diseases, infectious diseases, cancers of the cervix and prostate, etc.) and fetal fibronectin; - breast health (35.5%): digital mammography and breast biopsy solutions and systems; - gynecological surgery (15%): endometrial ablation devices, minimally invasive intervention systems for the hysteroscopic elimination of targeted intrauterine diseases (including fibroids and polyps). The group also offers fluid management systems for use in hysteroscopic procedures; - bone health (2.8%): bone imaging systems, bone sonometers and osteodensitometers for bone structure and density, and osteoporotic fractures risk assessment. Net sales break down by source of revenue between sales of products (81.4%) and services (18.6%). Net sales are distributed geographically as follows: the United States (75.9%), Europe (12.9%), Asia/Pacific (6.3%) and other (4.9%).

Sector

Advanced Medical Equipment & Technology

Calendar

2024-07-23 - Q3 2024 Earnings Release (Projected)

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Hologic, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

75.02 USD

Average target price

85 USD

Spread / Average Target

+13.30%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
HOLOGIC, INC.	+5.00%	17.49B
THERMO FISHER SCIENTIFIC	+12.15%	228B
DANAHER CORPORATION	+14.90%	196B
INTUITIVE SURGICAL, INC.	+18.22%	141B
BOSTON SCIENTIFIC CORPORATION	+29.15%	110B
SIEMENS HEALTHINEERS AG	+0.53%	65.88B
EDWARDS LIFESCIENCES CORPORATION	+16.92%	54.3B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+6.33%	52.39B
AGILENT TECHNOLOGIES, INC.	+10.93%	45.22B
GE HEALTHCARE TECHNOLOGIES INC.	+5.87%	37.12B

Other Advanced Medical Equipment & Technology

Hologic, Inc.

Equities

HOLX

US4364401012

Advanced Medical Equipment & Technology

Hologic, Inc. Reports Impairment of Intangible Assets for the Second Quarter Ended March 30, 2024

Latest news about Hologic, Inc.

Chart Hologic, Inc.

Company Profile

Income Statement Evolution

Ratings for Hologic, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Advanced Medical Equipment & Technology